Page 4 - Aser Surgery News Today

As the healthcare industry grapples with various challenges, from workforce shortages to complex coding intricacies, embracing AI can empower revenue cycle professionals to envision a future with reduced denials, optimized revenue, and fortified financial health.

MedCity INVEST 2024, scheduled for May 21-22 at the Ritz Carlton hotel in Chicago, is the ideal event to discuss healthcare funding with investors looking for investment opportunities. 

Research shows that 44 veterans die each day as a result of suicide or self-injury. At ViVE 2024, Shereef Elnahal, the U.S. Department of Veterans Affairs’ under secretary for health, declared that even one veteran dying by suicide is too many — and promised that the VA is pursuing partnerships aimed at addressing this harrowing problem.

In this month’s episode, Senior Reporter Katie Adams discussed some executive hires, promotions and departures that recently occurred in the healthcare world, as well as layoffs affecting the industry. We also hear from Adam Petrich, who recently became QuantHealth’s first chief medical officer.

Regenerative medicine startup Pelage Pharmaceuticals has clinical data showing its small molecule activated hair follicle stem cells. GV led a Series A round that funded the UCLA spinout’s Phase 1 clinical trial and will also support Phase 2 testing this year.

In this episode, the CEO of Lumen talks about the sleek consumer device and why he is at a b-to-b healthcare conference.

Adopting an infinite mindset could be the antidote to the slow destruction of healthcare by short-term thinking.

A Janux Therapeutics T cell engager has early clinical data showing improvement in cases of advanced prostate cancer, validating the technology platform that produced the therapy. Janux is now leveraging its soaring stock price to raise $175 million in a stock offering.

In the venture capital community, there’s a bit of a debate about what matters more to digital health investors in today's fundraising environment — growth or profitability. Cathy Gao, a partner at Sapphire Ventures, thinks VCs are still putting a premium on growth, but she noted that the conversation is very nuanced.

The FMT era has been productive, but now it’s time to rally together as an industry to accelerate next-generation LBP drug discovery, development and FDA approval.